Dosing & Uses
Dosage Forms & Strengths
tablet extended release
- 11mg
oral suspension
- 12mg/5mL
oral liquid
- 1mg/1mL
- 2 mg/5mL
Symptomatic relief of upper respiratory symptoms, including nasal congestion, associated with allergy or common cold
4 mg PO q4-6hr (no more than 24 mg qDay) PRN
Extended-release: 8-12 mg tablet PO q12hr or 12-24 mg capsule PO qDay
Other Indications & Uses
Perennial & seasonal allergic & vasomotor rhinitis, urticaria, angioedema, anaphylactic reactions, pruritus, allergic conjunctivitis
Dosage Forms & Strengths
tablet
- 11mg
oral suspension
- 12mg/5mL
liquid
- 1mg/mL
- 2mg/5mL
Symptomatic relief of upper respiratory symptoms, including nasal congestion, associated with allergy or common cold
<12 Years Old
Nonanticholinergic antihistamines should be considered first when treating allergic reactions (Beers Criteria)
Avoid use in elderly because of high incidence of anticholinergic effects
Clearance reduced with advanced age, greater risk of confusion, dry mouth, constipation, and other anticholinergic effects and toxicity
May exacerbate existing lower urinary conditions or benign prostatic hyperplasia
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (0)
Serious - Use Alternative (9)
- calcium/magnesium/potassium/sodium oxybates
brompheniramine, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- eluxadoline
brompheniramine, eluxadoline. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that cause constipation. Increases risk for constipation related serious adverse reactions.
- isocarboxazid
isocarboxazid increases effects of brompheniramine by Other (see comment). Avoid or Use Alternate Drug. Comment: Isocarboxazid should not be administered in combination with antihistamines because of potential additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. .
- metoclopramide intranasal
brompheniramine, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.
- olopatadine intranasal
brompheniramine and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- pitolisant
brompheniramine decreases effects of pitolisant by Other (see comment). Avoid or Use Alternate Drug. Comment: Pitolisant increases histamine levels in the brain; therefore, H1 receptor antagonists that cross the blood-brain barrier may reduce the efficacy of pitolisant.
- selinexor
selinexor, brompheniramine. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.
- sodium oxybate
brompheniramine, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- tranylcypromine
tranylcypromine increases effects of brompheniramine by Other (see comment). Avoid or Use Alternate Drug. Comment: Tranylcypromine should not be administered in combination with antihistamines because of potential additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. .
Monitor Closely (211)
- acrivastine
acrivastine and brompheniramine both increase sedation. Use Caution/Monitor.
- albuterol
brompheniramine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- alfentanil
brompheniramine and alfentanil both increase sedation. Use Caution/Monitor.
- alprazolam
brompheniramine and alprazolam both increase sedation. Use Caution/Monitor.
- amifampridine
brompheniramine increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.
- amisulpride
amisulpride and brompheniramine both increase sedation. Use Caution/Monitor.
- amitriptyline
brompheniramine and amitriptyline both increase sedation. Use Caution/Monitor.
- amobarbital
brompheniramine and amobarbital both increase sedation. Use Caution/Monitor.
- amoxapine
brompheniramine and amoxapine both increase sedation. Use Caution/Monitor.
- apomorphine
brompheniramine and apomorphine both increase sedation. Use Caution/Monitor.
- arformoterol
brompheniramine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- aripiprazole
brompheniramine and aripiprazole both increase sedation. Use Caution/Monitor.
- armodafinil
brompheniramine increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- asenapine
asenapine and brompheniramine both increase sedation. Use Caution/Monitor.
- asenapine transdermal
asenapine transdermal and brompheniramine both increase sedation. Use Caution/Monitor.
- avapritinib
avapritinib and brompheniramine both increase sedation. Use Caution/Monitor.
- azelastine
azelastine and brompheniramine both increase sedation. Use Caution/Monitor.
- baclofen
brompheniramine and baclofen both increase sedation. Use Caution/Monitor.
- belladonna and opium
brompheniramine and belladonna and opium both increase sedation. Use Caution/Monitor.
- benperidol
brompheniramine and benperidol both increase sedation. Use Caution/Monitor.
- benzhydrocodone/acetaminophen
benzhydrocodone/acetaminophen and brompheniramine both increase sedation. Use Caution/Monitor.
- benzphetamine
brompheniramine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- brexanolone
brexanolone, brompheniramine. Either increases toxicity of the other by sedation. Use Caution/Monitor.
- brexpiprazole
brexpiprazole and brompheniramine both increase sedation. Use Caution/Monitor.
- brimonidine
brimonidine and brompheniramine both increase sedation. Use Caution/Monitor.
- brivaracetam
brivaracetam and brompheniramine both increase sedation. Use Caution/Monitor.
- buprenorphine
brompheniramine and buprenorphine both increase sedation. Use Caution/Monitor.
- buprenorphine buccal
brompheniramine and buprenorphine buccal both increase sedation. Use Caution/Monitor.
- buprenorphine subdermal implant
buprenorphine subdermal implant and brompheniramine both increase sedation. Use Caution/Monitor.
- buprenorphine transdermal
buprenorphine transdermal and brompheniramine both increase sedation. Use Caution/Monitor.
- butabarbital
brompheniramine and butabarbital both increase sedation. Use Caution/Monitor.
- butalbital
brompheniramine and butalbital both increase sedation. Use Caution/Monitor.
- butorphanol
brompheniramine and butorphanol both increase sedation. Use Caution/Monitor.
- caffeine
brompheniramine increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- carbinoxamine
brompheniramine and carbinoxamine both increase sedation. Use Caution/Monitor.
- carisoprodol
brompheniramine and carisoprodol both increase sedation. Use Caution/Monitor.
- cenobamate
cenobamate, brompheniramine. Either increases effects of the other by sedation. Use Caution/Monitor.
- chloral hydrate
brompheniramine and chloral hydrate both increase sedation. Use Caution/Monitor.
- chlordiazepoxide
brompheniramine and chlordiazepoxide both increase sedation. Use Caution/Monitor.
- chlorpheniramine
brompheniramine and chlorpheniramine both increase sedation. Use Caution/Monitor.
- chlorpromazine
brompheniramine and chlorpromazine both increase sedation. Use Caution/Monitor.
- chlorzoxazone
brompheniramine and chlorzoxazone both increase sedation. Use Caution/Monitor.
- cinnarizine
brompheniramine and cinnarizine both increase sedation. Use Caution/Monitor.
- clemastine
brompheniramine and clemastine both increase sedation. Use Caution/Monitor.
- clobazam
brompheniramine, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).
- clomipramine
brompheniramine and clomipramine both increase sedation. Use Caution/Monitor.
- clonazepam
brompheniramine and clonazepam both increase sedation. Use Caution/Monitor.
- clorazepate
brompheniramine and clorazepate both increase sedation. Use Caution/Monitor.
- clozapine
brompheniramine and clozapine both increase sedation. Use Caution/Monitor.
- codeine
brompheniramine and codeine both increase sedation. Use Caution/Monitor.
- cyclizine
brompheniramine and cyclizine both increase sedation. Use Caution/Monitor.
- cyclobenzaprine
brompheniramine and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- cyproheptadine
brompheniramine and cyproheptadine both increase sedation. Use Caution/Monitor.
- dantrolene
brompheniramine and dantrolene both increase sedation. Use Caution/Monitor.
- daridorexant
brompheniramine and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- desflurane
desflurane and brompheniramine both increase sedation. Use Caution/Monitor.
- desipramine
brompheniramine and desipramine both increase sedation. Use Caution/Monitor.
- deutetrabenazine
brompheniramine and deutetrabenazine both increase sedation. Use Caution/Monitor.
- dexchlorpheniramine
brompheniramine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.
- dexfenfluramine
brompheniramine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dexmedetomidine
brompheniramine and dexmedetomidine both increase sedation. Use Caution/Monitor.
- dexmethylphenidate
brompheniramine increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dextroamphetamine
brompheniramine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dextromoramide
brompheniramine and dextromoramide both increase sedation. Use Caution/Monitor.
- diamorphine
brompheniramine and diamorphine both increase sedation. Use Caution/Monitor.
- diazepam
brompheniramine and diazepam both increase sedation. Use Caution/Monitor.
- diazepam intranasal
diazepam intranasal, brompheniramine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.
- diethylpropion
brompheniramine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- difelikefalin
difelikefalin and brompheniramine both increase sedation. Use Caution/Monitor.
- difenoxin hcl
brompheniramine and difenoxin hcl both increase sedation. Use Caution/Monitor.
- dimenhydrinate
brompheniramine and dimenhydrinate both increase sedation. Use Caution/Monitor.
- diphenhydramine
brompheniramine and diphenhydramine both increase sedation. Use Caution/Monitor.
- diphenoxylate hcl
brompheniramine and diphenoxylate hcl both increase sedation. Use Caution/Monitor.
- dipipanone
brompheniramine and dipipanone both increase sedation. Use Caution/Monitor.
- dobutamine
brompheniramine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- donepezil transdermal
donepezil transdermal, brompheniramine. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.
- dopamine
brompheniramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dopexamine
brompheniramine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dosulepin
brompheniramine and dosulepin both increase sedation. Use Caution/Monitor.
- doxepin
brompheniramine and doxepin both increase sedation. Use Caution/Monitor.
- doxylamine
brompheniramine and doxylamine both increase sedation. Use Caution/Monitor.
- droperidol
brompheniramine and droperidol both increase sedation. Use Caution/Monitor.
- ephedrine
brompheniramine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- epinephrine
brompheniramine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- epinephrine racemic
brompheniramine increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- esketamine intranasal
esketamine intranasal, brompheniramine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.
- estazolam
brompheniramine and estazolam both increase sedation. Use Caution/Monitor.
- ethanol
brompheniramine and ethanol both increase sedation. Use Caution/Monitor.
- etomidate
etomidate and brompheniramine both increase sedation. Use Caution/Monitor.
- fenfluramine
brompheniramine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- fentanyl
fentanyl, brompheniramine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.
fentanyl and brompheniramine both increase sedation. Use Caution/Monitor. - fentanyl intranasal
fentanyl intranasal, brompheniramine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.
fentanyl intranasal and brompheniramine both increase sedation. Use Caution/Monitor. - fentanyl iontophoretic transdermal system
fentanyl iontophoretic transdermal system and brompheniramine both increase sedation. Use Caution/Monitor.
- fentanyl transdermal
fentanyl transdermal, brompheniramine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.
fentanyl transdermal and brompheniramine both increase sedation. Use Caution/Monitor. - fentanyl transmucosal
fentanyl transmucosal, brompheniramine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.
- flibanserin
brompheniramine and flibanserin both increase sedation. Modify Therapy/Monitor Closely. Risk for sedation increased if flibanserin is coadministration with other CNS depressants.
- fluphenazine
brompheniramine and fluphenazine both increase sedation. Use Caution/Monitor.
- flurazepam
brompheniramine and flurazepam both increase sedation. Use Caution/Monitor.
- formoterol
brompheniramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- gabapentin
gabapentin, brompheniramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- gabapentin enacarbil
gabapentin enacarbil, brompheniramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- ganaxolone
brompheniramine and ganaxolone both increase sedation. Use Caution/Monitor.
- glycopyrronium tosylate topical
glycopyrronium tosylate topical, brompheniramine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.
- gotu kola
gotu kola increases effects of brompheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- haloperidol
brompheniramine and haloperidol both increase sedation. Use Caution/Monitor.
- hawthorn
hawthorn increases effects of brompheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- hops
hops increases effects of brompheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- hyaluronidase
brompheniramine decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. Comment: Antihistamines, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect.
- hydromorphone
brompheniramine and hydromorphone both increase sedation. Use Caution/Monitor.
- hydroxyzine
brompheniramine and hydroxyzine both increase sedation. Use Caution/Monitor.
- iloperidone
brompheniramine and iloperidone both increase sedation. Use Caution/Monitor.
- imipramine
brompheniramine and imipramine both increase sedation. Use Caution/Monitor.
- isoproterenol
brompheniramine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- kava
kava increases effects of brompheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- ketamine
ketamine and brompheniramine both increase sedation. Use Caution/Monitor.
- ketotifen, ophthalmic
brompheniramine and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.
- lasmiditan
lasmiditan, brompheniramine. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.
- lemborexant
lemborexant, brompheniramine. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.
- levalbuterol
brompheniramine increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- levorphanol
brompheniramine and levorphanol both increase sedation. Use Caution/Monitor.
- lisdexamfetamine
brompheniramine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- lofepramine
brompheniramine and lofepramine both increase sedation. Use Caution/Monitor.
- lofexidine
brompheniramine and lofexidine both increase sedation. Use Caution/Monitor.
- loprazolam
brompheniramine and loprazolam both increase sedation. Use Caution/Monitor.
- lorazepam
brompheniramine and lorazepam both increase sedation. Use Caution/Monitor.
- lormetazepam
brompheniramine and lormetazepam both increase sedation. Use Caution/Monitor.
- loxapine
brompheniramine and loxapine both increase sedation. Use Caution/Monitor.
- loxapine inhaled
brompheniramine and loxapine inhaled both increase sedation. Use Caution/Monitor.
- lurasidone
lurasidone, brompheniramine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.
- maprotiline
brompheniramine and maprotiline both increase sedation. Use Caution/Monitor.
- marijuana
brompheniramine and marijuana both increase sedation. Use Caution/Monitor.
- melatonin
brompheniramine and melatonin both increase sedation. Use Caution/Monitor.
- meperidine
brompheniramine and meperidine both increase sedation. Use Caution/Monitor.
- meprobamate
brompheniramine and meprobamate both increase sedation. Use Caution/Monitor.
- metaproterenol
brompheniramine increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- metaxalone
brompheniramine and metaxalone both increase sedation. Use Caution/Monitor.
- methadone
brompheniramine and methadone both increase sedation. Use Caution/Monitor.
- methamphetamine
brompheniramine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- methocarbamol
brompheniramine and methocarbamol both increase sedation. Use Caution/Monitor.
- methylenedioxymethamphetamine
brompheniramine increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- midazolam
brompheniramine and midazolam both increase sedation. Use Caution/Monitor.
- midazolam intranasal
midazolam intranasal, brompheniramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.
- midodrine
brompheniramine increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- mirtazapine
brompheniramine and mirtazapine both increase sedation. Use Caution/Monitor.
- modafinil
brompheniramine increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- morphine
brompheniramine and morphine both increase sedation. Use Caution/Monitor.
- motherwort
brompheniramine and motherwort both increase sedation. Use Caution/Monitor.
- moxonidine
brompheniramine and moxonidine both increase sedation. Use Caution/Monitor.
- nabilone
brompheniramine and nabilone both increase sedation. Use Caution/Monitor.
- nalbuphine
brompheniramine and nalbuphine both increase sedation. Use Caution/Monitor.
- norepinephrine
brompheniramine increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- nortriptyline
brompheniramine and nortriptyline both increase sedation. Use Caution/Monitor.
- olanzapine
brompheniramine and olanzapine both increase sedation. Use Caution/Monitor.
- opium tincture
brompheniramine and opium tincture both increase sedation. Use Caution/Monitor.
- orphenadrine
brompheniramine and orphenadrine both increase sedation. Use Caution/Monitor.
- oxazepam
brompheniramine and oxazepam both increase sedation. Use Caution/Monitor.
- oxycodone
brompheniramine and oxycodone both increase sedation. Use Caution/Monitor.
- oxymorphone
brompheniramine and oxymorphone both increase sedation. Use Caution/Monitor.
- paliperidone
brompheniramine and paliperidone both increase sedation. Use Caution/Monitor.
- papaveretum
brompheniramine and papaveretum both increase sedation. Use Caution/Monitor.
- papaverine
brompheniramine and papaverine both increase sedation. Use Caution/Monitor.
- passion flower
passion flower increases effects of brompheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- pentazocine
brompheniramine and pentazocine both increase sedation. Use Caution/Monitor.
- pentobarbital
brompheniramine and pentobarbital both increase sedation. Use Caution/Monitor.
- perampanel
perampanel and brompheniramine both increase sedation. Use Caution/Monitor.
- perphenazine
brompheniramine and perphenazine both increase sedation. Use Caution/Monitor.
- phendimetrazine
brompheniramine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenelzine
phenelzine increases effects of brompheniramine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Coadministration of phenelzine and antihistamines may result in additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. .
- phenobarbital
brompheniramine and phenobarbital both increase sedation. Use Caution/Monitor.
- phentermine
brompheniramine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenylephrine
brompheniramine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenylephrine PO
brompheniramine increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- pholcodine
brompheniramine and pholcodine both increase sedation. Use Caution/Monitor.
- pimozide
brompheniramine and pimozide both increase sedation. Use Caution/Monitor.
- pirbuterol
brompheniramine increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pregabalin
pregabalin, brompheniramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- primidone
brompheniramine and primidone both increase sedation. Use Caution/Monitor.
- prochlorperazine
brompheniramine and prochlorperazine both increase sedation. Use Caution/Monitor.
- promethazine
brompheniramine and promethazine both increase sedation. Use Caution/Monitor.
- propofol
propofol and brompheniramine both increase sedation. Use Caution/Monitor.
- propylhexedrine
brompheniramine increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- protriptyline
brompheniramine and protriptyline both increase sedation. Use Caution/Monitor.
- quazepam
brompheniramine and quazepam both increase sedation. Use Caution/Monitor.
- quetiapine
brompheniramine and quetiapine both increase sedation. Use Caution/Monitor.
- ramelteon
brompheniramine and ramelteon both increase sedation. Use Caution/Monitor.
- risperidone
brompheniramine and risperidone both increase sedation. Use Caution/Monitor.
- salmeterol
brompheniramine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- scullcap
brompheniramine and scullcap both increase sedation. Use Caution/Monitor.
- secobarbital
brompheniramine and secobarbital both increase sedation. Use Caution/Monitor.
- sevoflurane
sevoflurane and brompheniramine both increase sedation. Use Caution/Monitor.
- shepherd's purse
brompheniramine and shepherd's purse both increase sedation. Use Caution/Monitor.
- sufentanil
brompheniramine and sufentanil both increase sedation. Use Caution/Monitor.
- tapentadol
brompheniramine and tapentadol both increase sedation. Use Caution/Monitor.
- temazepam
brompheniramine and temazepam both increase sedation. Use Caution/Monitor.
- terbutaline
brompheniramine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- thioridazine
brompheniramine and thioridazine both increase sedation. Use Caution/Monitor.
- thiothixene
brompheniramine and thiothixene both increase sedation. Use Caution/Monitor.
- topiramate
brompheniramine and topiramate both increase sedation. Modify Therapy/Monitor Closely.
- tramadol
brompheniramine and tramadol both increase sedation. Use Caution/Monitor.
- trazodone
brompheniramine and trazodone both increase sedation. Use Caution/Monitor.
- triazolam
brompheniramine and triazolam both increase sedation. Use Caution/Monitor.
- triclofos
brompheniramine and triclofos both increase sedation. Use Caution/Monitor.
- trifluoperazine
brompheniramine and trifluoperazine both increase sedation. Use Caution/Monitor.
- trimipramine
brompheniramine and trimipramine both increase sedation. Use Caution/Monitor.
- triprolidine
brompheniramine and triprolidine both increase sedation. Use Caution/Monitor.
- valerian
valerian increases effects of brompheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- xylometazoline
brompheniramine increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- yohimbine
brompheniramine increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ziconotide
brompheniramine and ziconotide both increase sedation. Use Caution/Monitor.
- ziprasidone
brompheniramine and ziprasidone both increase sedation. Use Caution/Monitor.
- zotepine
brompheniramine and zotepine both increase sedation. Use Caution/Monitor.
Minor (6)
- ashwagandha
ashwagandha increases effects of brompheniramine by pharmacodynamic synergism. Minor/Significance Unknown. May enhance CNS depression.
- brimonidine
brimonidine increases effects of brompheniramine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- eucalyptus
brompheniramine and eucalyptus both increase sedation. Minor/Significance Unknown.
- nettle
nettle increases effects of brompheniramine by pharmacodynamic synergism. Minor/Significance Unknown. (High dose nettle; theoretical interaction) May enhance CNS depression.
- sage
brompheniramine and sage both increase sedation. Minor/Significance Unknown.
- Siberian ginseng
Siberian ginseng increases effects of brompheniramine by pharmacodynamic synergism. Minor/Significance Unknown. May enhance CNS depression.
Adverse Effects
Varies in incidence & severity with the individual drug; also individual patients vary in susceptibility
Frequency Not Defined
CNS depression
Drowsiness
Sedation ranging from mild drowsiness to deep sleep (most frequent)
Dizziness
Lassitude
Disturbed coordination
Muscular weakness
Restlessness, insomnia, tremors, euphoria, nervousness, delirium, palpitation, seizures is less common
Epigastric distress
Anorexia
Nausea
Vomiting
Diarrhea
Constipation
Cholestasis, hepatitis, hepatic failure, hepatic function abnormality, jaundice is rare
Tachycardia, palpitation ECG changes (eg, widened QRS)
Arrhythmias (eg, extrasystole, heart block)
Hypotension
Hypertension
Dizziness, sedation, and hypotension may occur in geriatric patients
Dryness of mouth, nose, and throat
Dysuria
Urinary retention
Impotence
Vertigo
Visual disturbances
Blurred vision
Diplopia; tinnitus
Acute labyrinthitis
Insomnia
Tremors
Nervousness
Irritability
Facial dyskinesia
Tightness of the chest
Thickening of bronchial secretions
Wheezing
Nasal stuffiness
Sweating
Chills
Early menses
Toxic psychosis
Headache
Faintness
Paresthesia
Agranulocytosis
Hemolytic anemia
Leukopenia
Thrombocytopenia
Pancytopenia
Warnings
Contraindications
Newborn infants, premature infants
Nursing mothers
Severe hypertension, severe coronary artery disease, severe ischemic heart disease
Within 14 days of taking monoamine oxidase (MAO) inhibitors
Narrow-angle glaucoma
Urinary retention
Peptic ulcer
During asthma attack
Treatment of lower respiratory tract conditions including asthma
Caution
Therapy may diminish mental alertness, and may cause hyperexcitability, especially in children
At doses higher than recommended dose, nervousness, dizziness, or sleeplessness may occur
Especially in infants and small children, antihistamines in overdosage may cause hallucinations, convulsions, and death
Use with caution in patients with hypertension, ischemic heart disease, and persons >60 years old
Not for administration to children who have a chronic pulmonary disease, breathing problems such as chronic bronchitis, glaucoma, or those who are taking sedatives or tranquilizers without first consulting with a doctor
Use caution in patients with hypertension, diabetes mellitus, ischemic heart disease, hyperthyroidism, increased intraocular pressure, and prostatic hypertrophy
Do not exceed recommended dosage
Discontinue use and contact healthcare professional if nervousness, dizziness, or sleeplessness occurs
Drug interaction overview
- Not for use in patients taking a prescription monoamine oxidase (MAO) inhibitor (certain drugs used for depression, psychiatric or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping MAO inhibitor
- MAO inhibitors prolong and intensify anticholinergic effects of antihistamines and may enhance effect of pseudoephedrine HCl
- Sympathomimetic agents may reduce effects of anti-hypertensive drugs
- Antihistamines have additive effects with alcohol and other CNS (central nervous system) depressants (hypnotics, sedatives, tranquilizers, anti-anxiety agents, etc)
Pregnancy & Lactation
Pregnancy
Animal reproductive studies not performed with brompheniramine; also, not known if it can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity; therapy should be given to a pregnant woman only if clearly needed
Lactation
Because of higher risk of intolerance of antihistamines in small infants generally, and in newborns and premature in particular, therapy is contraindicated in nursing mothers
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Histamine H1-receptor antagonist
Pharmacokinetics
Half-Life: 11.8-34.7 hr
Onset: 30 min
Peak Plasma Time: 2-5 hr
Vd: 11.7 L/kg
Metabolism: mainly liver
Metabolites: Propionic acid derivative conjugated with glycine
Excretion: urine
Antihistamine activity: high
Sedative effect: Low
Anticholinergic effects: Moderate
Duration
- Antihistamine: 3-9 hr, may last 48 hr
- Antipruritic: 9-24 hr
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.